Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure
1 other identifier
interventional
120
1 country
1
Brief Summary
Hypertension affects about 30% of the United Kingdom population and is causally implicated in the aetiology of renal disease, cardiovascular disease and stroke. Ageing, obesity, a poor diet and low levels of physical activity are all risk factors. Studies have shown that adherence to a Mediterranean diet is protective against hypertension and its associated morbidities; olive oil is believed to be a key beneficially bioactive component of that diet. As a source of lipids olive oil is an unremarkable blend of monounsaturated, polyunsaturated and saturated fatty acids; it is however rich in phenolic compounds, principally oleuropein and hydroxytyrosol, which may be of benefit to health. A recent randomised intervention trial in predominantly hypertensive volunteers showed that adherence to a Mediterranean diet supplemented with extra virgin olive oil, reduced blood pressure and other measures of cardiovascular disease risk. Olive phenolics can be extracted cheaply from the waste products of olive oil manufacture, such as the plant leaf and these are used as dietary supplements. In intervention studies in hypertensive or borderline hypertensive patients, olive leaf extract consumption has been shown to reduce blood pressure. Another intervention with established efficacy for improving blood pressure is to increase physical activity. The 'Start Active, Stay Active', Chief Medical Officers report on physical activity recommends that adults achieve 150 minutes of moderate intensity physical activity per week, while data in that report suggest that fewer than 40% of adult men and 30% of adult women achieve these targets. Adherence to the physical activity guidelines may in fact be much worse in sub-sections of the population at higher risk of hypertension. From a public health perspective, holistic guidelines for the prevention of hypertension, or its early diagnosis and management, based around a healthy diet and lifestyle are preferable to pharmaceutical intervention. Lifestyle interventions are economically favourable and they come with fewer side effects and perhaps wider health benefits than antihypertensive drugs. The aim of the study is to evidence the synergistic benefits of consuming plant (and specifically olive) phenolics alongside achieving the recommended guidelines for physical activity in individuals with elevated blood pressure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2013
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 10, 2015
CompletedFirst Posted
Study publicly available on registry
April 21, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedMay 30, 2016
May 1, 2016
2 years
April 10, 2015
May 27, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Blood pressure measured via 24 hour ambulatory blood pressure monitors
measured using the ScanMed Oscillometric Ambulatory blood pressure deviceVolunteers will be asked to wear the device which will be programmed to record BP measurements every 30 minutes during the day (7am-10pm) and every hour by night (10pm-7am)
12 weeks
Secondary Outcomes (7)
Average plasma glucose concentration
12 weeks
Vascular function assessed by pulse wave velocity (PWV)
12 weeks
Plasma biomarkers of endothelial function including nitric oxide, vascular cell adhesion molecule (VCAM), Inter-Cellular Adhesion Molecule (ICAM), E-selectin, von Willebrand factor
12 weeks
Fasting lipid profile including measures of total, low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, triglycerides and non-esterified fatty acids
12 weeks
Indices of insulin resistance derived from fasted measures of glucose, insulin and non-esterified fatty acids (revised QUICKI statistical analysis)
12 weeks
- +2 more secondary outcomes
Study Arms (4)
Placebo control
PLACEBO COMPARATOR2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
Olive leaf extract
ACTIVE COMPARATOR2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
Physical activity
PLACEBO COMPARATOR2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
Physical activity and olive leaf extract
ACTIVE COMPARATOR2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
Interventions
132 mg of oleuropein per day suspended in olive leaf extract 700 mg
700 mg Maltodextrin per day
Eligibility Criteria
You may qualify if:
- Men and women
- BMI \>25kg/m2
- Not having suffered a myocardial infarction/stroke in the past 12 months
- Not diabetic (diagnosed or fasting glucose \> 7 mmol/l) or suffer from other endocrine disorders
- Not suffering from renal or bowel disease or have a history of cholestatic liver or pancreatitis
- Not on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation
- No history of alcohol misuse
- Not planning or on a weight reducing regime
- Not taking any fish oil, fatty acid or vitamin and mineral supplements
- Non smokers
You may not qualify if:
- Use of antibiotics within the previous 6 months
- History of alcohol or drug abuse
- Intake of any experimental drug within 4 weeks of the start of the study
- Excessive alcohol consumption (more than 21 units/wk male, 15 units/wk female)
- Females who are breast-feeding, may be pregnant, or of child-bearing potential and not using effective contraceptive precautions
- Have had recently (in the last 5 years) major surgery, which might limit participation in, or completion of, the study.
- On drug treatment for high blood fats, high blood pressure and blood clotting.
- Physical or mental diseases that are likely to limit participation or completion of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hugh Sinclair Unit of Human Nutrition
Reading, Berkshire, RG6 6AP, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel Commane, PhD
Reading University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure
Study Record Dates
First Submitted
April 10, 2015
First Posted
April 21, 2015
Study Start
April 1, 2013
Primary Completion
April 1, 2015
Study Completion
April 1, 2016
Last Updated
May 30, 2016
Record last verified: 2016-05